Calidi Biotherapeutics to Showcase RedTail Platform's T-Cell Engager Breakthrough at AACR 2026
Event summary
- Calidi Biotherapeutics will present new data on its RedTail platform at the AACR annual meeting from April 17-22, 2026.
- The company is developing a new candidate targeting TROP-2 using its in situ T-cell engager approach.
- CLD-401, the lead candidate from the RedTail platform, is expected to file an IND by the end of 2026.
- RedTail viruses can express both a functional T-cell engager and IL-15 SA at high concentrations in the tumor microenvironment.
- The company is pursuing additional T-cell engager targets like EGFR, EpCAM, and Nectin-4.
The big picture
Calidi Biotherapeutics is positioning its RedTail platform as a breakthrough in delivering genetic payloads to tumor sites, addressing a critical gap in the efficacy of T-cell engagers for solid tumors. The company's approach of remodeling the tumor microenvironment and confining expression of T-cell engagers to the tumor site could reshape the landscape of targeted cancer therapies. The strategic focus on high-unmet medical needs, such as non-small cell lung cancer and head and neck cancer, aligns with broader industry trends towards precision oncology.
What we're watching
- Clinical Validation
- Whether the RedTail platform can overcome historical limitations of T-cell engagers in solid tumors.
- Regulatory Progress
- The pace at which Calidi can advance CLD-401 through IND filing and into clinical trials.
- Strategic Partnerships
- How potential partnerships could accelerate the development and commercialization of the RedTail platform.
Related topics